Table of Contents
Introduction
Piracetam is a popular nootropic compound known for its alleged neuroprotective and anticonvulsant properties. Extensive clinical research, including limited human studies, suggests that it holds great promise for enhancing cognitive function and alleviating certain neurological conditions. Specifically, studies have shown that piracetam has the potential to enhance verbal learning abilities and alleviate symptoms of dyslexia. Furthermore, it has been observed that Piracetam dosage may enhance mental performance in individuals with dementia.
Piracetam is not authorized by the Food and Drug Administration in the United States. For this reason, purchase Piracetam the research chemicals for laboratory use only.
What is Piracetam?
Piracetam, a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), plays a significant role in modulating brain activity by slowing down its processes. It belongs to the racetam family, a group of synthetic compounds characterized by a pyrrolidone ring in their chemical structure.
The history of Piracetam is noteworthy, as it holds the distinction of being the first-ever racetam compound to be synthesized. In 1964, scientists at the Belgian pharmaceutical company UCB successfully produced Piracetam. Its introduction to the market occurred in the early 1970s, when it received approval in Europe for the treatment of vertigo and age-related disorders.
Throughout the years, numerous studies have explored the potential benefits of Piracetam. These investigations have revealed its potential as a nootropic agent with neuroprotective and anticonvulsant properties. Moreover, Piracetam has demonstrated promising results in reducing the occurrence of breath-holding spells in children.
A systematic review of these studies indicates that Piracetam may be capable of crossing the blood-brain barrier. Notably, it has a relatively long half-life, lasting between 5 and 8 hours, when compared to similar Piracetam-like compounds such as phenylpiracetam and aniracetam.
Key Features
- 98% Purity
- 125g
- Sold for research purposes only
- CAS Number: 7491-74-9
- Molar Mass: 142.158 g·mol−1
- Chemical Formula: C6H10N2O2
- IUPAC Name: 2-(2-Oxopyrrolidin-1-yl)acetamide
How Does It Work?
Piracetam’s precise mechanism of action has yet to be fully elucidated; however, several potential effects have been observed. Firstly, Piracetam has been found to potentially increase acetylcholine activity in the brain, which is a neurotransmitter involved in cognitive processes. This increase in acetylcholine levels may contribute to improved cognitive function and memory enhancement.
Secondly, Piracetam may alleviate mitochondrial dysfunction, which refers to impaired functioning of the mitochondria, the cellular powerhouses responsible for energy production. By mitigating mitochondrial dysfunction, Piracetam could potentially enhance cellular energy metabolism, promoting better overall brain function and cognitive performance.
Furthermore, Piracetam has been suggested to enhance neuroplasticity, which is the brain’s ability to reorganize and form new neural connections. By supporting neuroplasticity, Piracetam may facilitate learning, memory formation, and information processing.
While these observed effects provide valuable insights into Piracetam’s potential mechanisms, it is important to note that further research is necessary to fully understand and confirm these findings. Nonetheless, the existing evidence suggests that Piracetam’s multifaceted actions on acetylcholine activity, mitochondrial function, energy metabolism, and neuroplasticity may contribute to its cognitive-enhancing properties.
Potential Benefits of Piracetam
Piracetam and Schizophrenia
Clinical studies have suggested that adding Piracetam to existing treatment could possibly improve behavioral and cognitive functions in schizophrenic patients. In a placebo-controlled trial, piracetam-like drugs may potentially reduce symptoms of tardive dyskinesia, a condition characterized by involuntary movements, in individuals with schizophrenia. [R] [R]
Piracetam and Mental Performance
A double-blind placebo-controlled trial involving aging individuals without cognitive deterioration explored the effects of Piracetam administration on mental performance. The study showed that participants on Piracetam performed better in various tasks compared to those on placebo, indicating its potential use in treating reduced mental performance associated with disturbed alertness. [R]
Piracetam and Fetal Distress
A review from 1998 examined the effects of Piracetam on suspected fetal distress during labor. The review included a laboratory-controlled trial in which 96 test subjects were randomized to receive Piracetam or a placebo. The findings suggested that Piracetam treatment could potentially reduce the need for a cesarean section. However, further evidence is needed to fully evaluate the use of Piracetam for fetal distress during labor. [R]
Piracetam and Post-Stroke Recovery
A pilot study investigating Piracetam treatment for 12 weeks in test subjects recovering from a specific stroke showed potential improvements in aphasia symptoms. However, due to the unavailability of test subjects after the study, it is unclear whether these effects persisted post-treatment. Another systematic review of seven randomized clinical trials found that Piracetam potentially rehabilitated overall language impairment and benefited written language ability in post-stroke subjects. [R] [R]
Piracetam and Dyslexia
In a clinical trial conducted to investigate the effects of Piracetam on dyslexic subjects and healthy clinical participants, both groups were given either 800 mg of Piracetam capsules or a placebo. The results revealed promising findings, indicating that verbal learning could potentially increase by up to 15% in dyslexic test subjects and by 8.6% in healthy clinical participants. This suggests that Piracetam may have a positive impact on learning abilities in test subjects with dyslexia.
Additionally, a 36-week double-blind study involving younger test subjects administered a daily dose of 3.3 g Piracetam showed improved reaction times and easier recognition of language-related test prompts, suggesting enhanced feature analysis. [R] [R]
Piracetam and Myoclonus Epilepsy
Studies have demonstrated the effectiveness and tolerability of Piracetam in the treatment of myoclonus epilepsy. Higher doses, such as 24 g, were found to be more beneficial and effective than lower doses. The addition of Piracetam to existing anti-epileptic treatment resulted in marked improvements in myoclonus symptoms. Leading researchers recommend more studies regarding Piracetam as a first-line treatment for cortical myoclonus. [R] [R]
Piracetam and Mild Cognitive Disorders
In a study involving 104 test subjects with mild cognitive impairment or dementia, Piracetam treatment demonstrated the potential to improve memory and psychomotor functions. These improvements were observed after a few weeks of Piracetam administration. A meta-analysis of 19 studies further supported the potential efficacy of Piracetam in treating cognitive impairment and dementia in older laboratory subjects with various CNS disorders. [R] [R]
Precautions to Consider
When researching the use of Piracetam, it is essential to take certain precautions. Here are some precautions to keep in mind:
Observe best practices for studying research chemicals: Studying research chemicals requires a responsible and informed approach to ensure safety and meaningful scientific exploration. Research chemicals, also known as designer drugs or experimental compounds, are substances synthesized for scientific investigation or exploration of their properties.
Follow recommended dosage: Adhere to the recommended dosage instructions outlined on the product label. Avoid exceeding the suggested dose to minimize the risk of potential adverse effects among test subjects.
Potential Side Effects
As the pioneering nootropic, Piracetam has garnered significant attention and has been the subject of numerous clinical trials, as well as animal and cell-based studies. The collective findings from these studies suggest that Piracetam is generally considered safe for use. In long-term studies, doses as high as 24 grams per day have been administered without the occurrence of significant adverse effects.
However, it is worth noting that a pooled analysis of 91 double-blind, placebo-controlled studies identified a slight increase in the potential occurrence of certain side effects with Piracetam use. These side effects include weight gain, nervousness, depression, and asthenia (physical weakness or lack of energy). It is important to emphasize that the incidence of each of these events was reported to be less than 2%.
Conclusion
In conclusion, the benefits of Piracetam have been demonstrated through rigorous scientific investigations, including randomized controlled trials. This compound has shown promising potential in various clinical applications, particularly in the realms of cognitive enhancement and neurological disorders.
Piracetam, administered in the form of capsules, has been associated with improved cognitive performance in individuals with cognitive impairment. Studies have also indicated positive effects on schizophrenic patients, suggesting the compound’s role in improving behavioral and cognitive functions.
Moreover, piracetam has shown potential in diverse areas, such as post-stroke recovery, coronary bypass surgery, and novel clinical applications. Basic science research has provided insights into its molecular formula and mechanisms of action, including its influence on AMPA receptors and neuroplasticity.
The use of piracetam in Alzheimer’s disease and related cognitive disorders has been extensively explored in both preclinical and clinical studies, further supporting its cognitive benefits. Additionally, reviews have highlighted its potential effectiveness in enhancing choline availability, reducing anxiety, and supporting overall brain health.
Furthermore, piracetam has been regarded as a valuable nootropic research compound, offering possible preventive properties in the context of neurodegenerative diseases and promoting stable cognitive function. Its diverse forms and potential applications contribute to its wide recognition in the field of cognitive enhancement research.
Disclaimer:
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before purchasing RCD.bio. By completing your order and submitting payment, you agree to abide by the terms and conditions of our company. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If, for any reason, you are not completely satisfied with the product you receive, please contact us at support@rcdbio.co. Our team is dedicated to ensuring satisfaction among our customers.
Please note: All products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.
